Company profile for Abpro

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Abpro Corporation is a clinical-stage biotechnology company, that engages in developing next-generation antibody therapies, for patients with severe disease in multiple areas, including immuno-oncology/cancer, infectious disease, ophthalmology, and autoimmunity. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and endometrial cancers; ABP-201 for the treatment of vascular diseases of the eye;...
Abpro Corporation is a clinical-stage biotechnology company, that engages in developing next-generation antibody therapies, for patients with severe disease in multiple areas, including immuno-oncology/cancer, infectious disease, ophthalmology, and autoimmunity. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and endometrial cancers; ABP-201 for the treatment of vascular diseases of the eye; ABP-150 for gastric cancer; and ABP-300 for COVID-19. Abpro Corporation has partnership agreements with Essex Bio-Investment Ltd., AbMed Corporation, MedImmune Ltd., and Luye Pharma Group Ltd., Memorial Sloan Ketterin

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
68 Cummings Park Drive, Woburn, MA 01801
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/09/3202228/0/en/Abpro-Granted-Nasdaq-Listing-Extension-to-Pursue-Compliance-and-Strategic-Objectives.html

GLOBENEWSWIRE
09 Dec 2025

https://www.globenewswire.com/news-release/2025/11/04/3180471/0/en/Abpro-and-Celltrion-to-Present-Preclinical-Data-for-CT-P72-ABP-102-at-SITC-2025-Highlighting-a-Next-Generation-HER2-CD3-T-Cell-Engager.html

GLOBENEWSWIRE
04 Nov 2025

https://www.globenewswire.com/news-release/2025/04/27/3068834/0/en/Abpro-and-Celltrion-Unveil-Preclinical-Data-for-ABP-102-CT-P72-at-AACR-2025-Showcasing-Potential-Best-in-Class-HER2-x-CD3-T-Cell-Engager.html

GLOBENEWSWIRE
27 Apr 2025

https://www.globenewswire.com/news-release/2025/03/25/3049193/0/en/Abpro-Announces-Oral-Presentation-of-First-Preclinical-Data-for-ABP-102-CT-P72-a-Tetravalent-Bispecific-HER2-x-CD3-T-Cell-Engager-at-AACR-Annual-Meeting-2025.html

GLOBENEWSWIRE
25 Mar 2025

https://www.globenewswire.com/news-release/2025/03/10/3040232/0/en/Abpro-Statement-on-the-Departure-of-Former-CEO-Ian-Chan.html

GLOBENEWSWIRE
10 Mar 2025

https://www.globenewswire.com/news-release/2024/12/12/2996519/0/en/Abpro-Holdings-Celebrates-Closing-of-Business-Combination-with-Nasdaq-Bell-Ringing.html

GLOBENEWSWIRE
12 Dec 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty